Designed to Stimulate the Immune System to Attack and Destroy Cancer Cells

Our ImPACT platform genetically engineers cells to deliver gp96-chaperoned cancer testis antigens to activate a patient’s immune system.

The lead product, HS-110, is in a Phase 2 trial for treatment of non-small cell lung cancer (NSCLC)

More information on HS-110